CRISPR Therapeutics
NEWS
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.
As usual, it was a busy week for clinical trial updates. Here’s a look.
CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first two patients in the companies’ ongoing Phase I/II clinical trials of its CRISPR/Cas9 gene-editing therapy CTX001.
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
Synthego Snags $110 Million in Series C to Advance Vision of Making CRISPR Technology More Available
Genome engineering company Synthego received an infusion of $110 million from a Series C financing round led by Peter Thiel’s Founders Fund. The funds will be used to accelerate the company’s vision to make CRISPR technology more accessible to researchers.
JOBS
IN THE PRESS